Cannabis Law Report

JULY 21, 2021

The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.

Clinical Trials 105

Clinical Trials Chronic Pain Research and Development Treatment 105

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Veriheal

NOVEMBER 9, 2021

House of Representatives approved a bill on Friday that will allow researchers to study commercial cannabis sold in state-legal dispensaries instead of having to depend on government-grown cannabis, Marijuana Moment reports. The post Congress Passes Bill Allowing Researchers To Study Commercial Cannabis appeared first on Cannabis Central.

Clinical Trials 52

Clinical Trials Research and Development Chronic Pain Dispensary 52

Cannabis Law Report

AUGUST 10, 2021

Enters into the Chronic Pain Market with Psychedelics. binding letter of intent signed on July 12th 2021 to purchase certain assets of Cannvalate Pty Ltd. (“Shanti”), and all its assets focused on psychedelic MDMA-based drug development. The global chronic pain treatment market is predicted to progress at a CAGR of 6.5%

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

JUNE 21, 2021

Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. It’s an interesting analysis of who is using which strains to help treat which types of pain. The Upshot.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

AUGUST 2, 2021

Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain. Key findings from the pre-clinical trial are as follows: SCI-160 significantly alleviates pain up to 6 hours after injection as compared with vehicle-treated animals. TEL AVIV, Israel , Aug. after injection.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

SEPTEMBER 14, 2021

The new Radicle Science-OBX alliance fills an unmet need for rigorous scientific research in the cannabis industry and sets a new gold standard for CBD and minor cannabinoid product development.

Extraction 52

Extraction Research and Development Clinical Trials CBD 52